Celldex Therapeutics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Celldex Therapeutics stock.
View analyst ratings for Celldex Therapeutics or view top-rated stocks.

5 analysts have issued 12-month price objectives for Celldex Therapeutics' stock. Their CLDX stock forecasts range from $60.00 to $68.00. On average, they predict Celldex Therapeutics' stock price to reach $65.00 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price.
View analysts' price targets for Celldex Therapeutics or view top-rated stocks among Wall Street analysts.

Celldex Therapeutics' stock was trading at $38.64 at the beginning of 2022. Since then, CLDX shares have decreased by 25.8% and is now trading at $28.69.
View the best growth stocks for 2022 here.

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Celldex Therapeutics.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.75 million. Celldex Therapeutics had a negative net margin of 1,860.46% and a negative trailing twelve-month return on equity of 20.68%.
View Celldex Therapeutics' earnings history.

Celldex Therapeutics shares reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of CLDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.55%), RTW Investments LP (6.60%), BlackRock Inc. (6.52%), State Street Corp (5.74%), Vanguard Group Inc. (5.21%) and RA Capital Management L.P. (4.44%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics.

CLDX stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Invesco Ltd., Candriam Luxembourg S.C.A., BlackRock Inc., Ghost Tree Capital LLC, First Trust Advisors LP, Northern Trust Corp, and Kiwi Wealth Investments Limited Partnership. Company insiders that have sold Celldex Therapeutics company stock in the last two years include Diane C Young, Elizabeth Crowley, Richard M Wright, Samuel Bates Martin, and Sarah Cavanaugh.
View insider buying and selling activity for Celldex Therapeutics or view top insider-selling stocks.

CLDX stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Viking Global Investors LP, Kynam Capital Management LP, Woodline Partners LP, State Street Corp, RA Capital Management L.P., Polar Capital Holdings Plc, and Sessa Capital IM L.P..
View insider buying and selling activity for Celldex Therapeutics or or view top insider-buying stocks.

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLDX stock can currently be purchased for approximately $28.69.

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.34 billion and generates $4.65 million in revenue each year. The biopharmaceutical company earns $-70.51 million in net income (profit) each year or ($1.710010) on an earnings per share basis.

Celldex Therapeutics employs 132 workers across the globe.

Celldex Therapeutics was founded in 1983.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for Celldex Therapeutics is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at [email protected], or via fax at 908-454-1911.